Health Trials

HGBL, Nos

2

Review clinical trials related to HGBL, Nos. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

Participants needed: 12
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Feb 17, 2026Locations: 7
Eligibility criteria

While prior CD19-targeted therapies, including CAR T-cell therapy, do not exclud... [+8]

ECOG performance status ≥3. [+15]

Read more
Status: Recruiting

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the recommended Phase 2 dose of C402-CD19-CAR.

Participants needed: 18
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Exuma Biotechnology Ltd.Updated: Jun 13, 2025Locations: 1
Eligibility criteria

Male or female 18-75 years (inclusive); [+15]

History of receiving allogeneic hematopoietic stem cell transplantation, adoptiv... [+14]

Read more